PRECLINICAL AND CLINICAL ACTIVITY OF BMS-690514 IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER (NSCLC)

被引：0
|
作者：
Sbar, E. I. [1 ]
Wong, T. [2 ]
Salvati, M. [2 ]
Pathak, A. [2 ]
Mokliatchouk, O. [2 ]
Park, J. [2 ]
Harbison, C. [2 ]
Soria, J. [3 ]
机构：
[1] Bristol Myers Squibb Co, Global Clin Res, Princeton, NJ USA
[2] Bristol Myers Squibb Co, RandD, Princeton, NJ USA
[3] Inst Gustave Roussy, Villejuif, France
来源：
ANNALS OF ONCOLOGY | 2010年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：53 / 53
页数：1
相关论文
共 50 条
  • [1] PRECLINICAL AND CLINICAL ANTI-ANGIOGENIC ACTIVITY OF BMS-690514
    Wong, T.
    Fargnoli, J.
    Malone, H.
    Kukral, D.
    Henley, B.
    Harbison, C.
    Pathak, A.
    Lewin, A.
    Salvati, M.
    Krishnan, B.
    ANNALS OF ONCOLOGY, 2010, 21 : 56 - 57
  • [2] Tumor regression and pharmacodynamic (PD) biomarker validation in non-small cell lung cancer (NSCLC) patients treated with the ErbB/VEGFR inhibitor BMS-690514
    Bahleda, R.
    Soria, J.
    Harbison, C.
    Park, J.
    Felip, E.
    Hanna, N.
    Laurie, S. A.
    Armand, J.
    Shepherd, F. A.
    Herbst, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [3] Association of Clinical Activity of BMS-690514 With Veristrat® Classification and EGFR Status in NSCLC
    Harbison, C.
    Dongre, A.
    Chen, J.
    Xiao, Q.
    Mokliatchouk, O.
    Kurland, J.
    Salvati, M.
    Berman, D.
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (12) : S531 - S531
  • [4] Preclinical antitumor activity of BMS-690514, a panHER/VEGFR2 kinase inhibitor
    Gavai, Ashvinikumar V.
    Chen, Ping
    Norris, Derek
    Fink, Brian E.
    Mastalerz, Harold
    Zhao, Yufen
    Han, Wen-Ching
    Zhang, Guifen
    Johnson, Walter
    Ruediger, Edward
    Dextraze, Pierre
    Daris, Jean-Paul
    Kim, Soong-Hoon
    Leavitt, Kenneth
    Kim, Kyoung
    Lu, Songfeng
    Zheng, Peter
    Mathur, Arvind
    Vyas, Dinesh
    Tokarski, John S.
    Yu, Chiang
    Oppenheimer, Simone
    Zhang, Hongjian
    Lee, Francis
    Wong, Tai W.
    Vite, Gregory D.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2007, 233 : 794 - 794
  • [5] Treatment of non-small cell lung cancer (NSCLC)
    Zarogoulidis, Konstantinos
    Zarogoulidis, Paul
    Darwiche, Kaid
    Boutsikou, Efimia
    Machairiotis, Nikolaos
    Tsakiridis, Kosmas
    Katsikogiannis, Nikolaos
    Kougioumtzi, Ioanna
    Karapantzos, Ilias
    Huang, Haidong
    Spyratos, Dionysios
    JOURNAL OF THORACIC DISEASE, 2013, 5 : S389 - S396
  • [6] Clinical implications of telomerase activity in non-small cell lung cancer (NSCLC)
    Ramírez, JL
    Sancho, E
    Núñez, L
    Sánchez, JJ
    Balañá, C
    López, P
    Martín, C
    Monzó, M
    Rosell, R
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S39 - S39
  • [7] Clinical implications of telomerase activity in non-small cell lung cancer (NSCLC)
    Pifarre, A
    Monzo, M
    Martin, C
    Sanchez, JJ
    Barnadas, A
    Rosell, R
    ANNALS OF ONCOLOGY, 1998, 9 : 92 - 92
  • [8] The cost of non-small cell lung cancer (NSCLC) treatment
    Vergnenegre, A.
    ONCOLOGIE, 2012, 14 (05) : 310 - 315
  • [9] SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2015
    Garcia-Campelo, R.
    Bernabe, R.
    Cobo, M.
    Corral, J.
    Coves, J.
    Domine, M.
    Nadal, E.
    Rodriguez-Abreu, D.
    Vinolas, N.
    Massuti, B.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2015, 17 (12): : 1020 - 1029
  • [10] SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2013
    C. Camps
    E. Felip
    R. García-Campelo
    J. M. Trigo
    P. Garrido
    Clinical and Translational Oncology, 2013, 15 : 977 - 984
12345